Search

Your search keyword '"Aetesam-ur-Rahman, Muhammad"' showing total 23 results
Start Over Author "Aetesam-ur-Rahman, Muhammad"
23 results on '"Aetesam-ur-Rahman, Muhammad"'

Catalog

Books, media, physical & digital resources
See catalog results

4. Fractional Flow Reserve-Guided Stent Optimisation in Focal and Diffuse Coronary Artery Disease

Author

Ohashi, Hirofumi, primary, Collison, Damien, additional, Mizukami, Takuya, additional, Didagelos, Matthaios, additional, Sakai, Koshiro, additional, Aetesam-ur-Rahman, Muhammad, additional, Munhoz, Daniel, additional, McCartney, Peter, additional, Ford, Thomas J., additional, Lindsay, Mitchell, additional, Shaukat, Aadil, additional, Rocchiccioli, Paul, additional, Brogan, Richard, additional, Watkins, Stuart, additional, McEntegart, Margaret, additional, Good, Richard, additional, Robertson, Keith, additional, O’Boyle, Patrick, additional, Davie, Andrew, additional, Khan, Adnan, additional, Hood, Stuart, additional, Eteiba, Hany, additional, Amano, Tetsuya, additional, Sonck, Jeroen, additional, Berry, Colin, additional, De Bruyne, Bernard, additional, Oldroyd, Keith G., additional, and Collet, Carlos, additional more...

Published
2023
Full Text
View/download PDF

5. Angina After Percutaneous Coronary Intervention: Patient and Procedural Predictors

Author

Collison, Damien, primary, Copt, Samuel, additional, Mizukami, Takuya, additional, Collet, Carlos, additional, McLaren, Ruth, additional, Didagelos, Matthaios, additional, Aetesam-ur-Rahman, Muhammad, additional, McCartney, Peter, additional, Ford, Thomas J., additional, Lindsay, Mitchell, additional, Shaukat, Aadil, additional, Rocchiccioli, Paul, additional, Brogan, Richard, additional, Watkins, Stuart, additional, McEntegart, Margaret, additional, Good, Richard, additional, Robertson, Keith, additional, O’Boyle, Patrick, additional, Davie, Andrew, additional, Khan, Adnan, additional, Hood, Stuart, additional, Eteiba, Hany, additional, Berry, Colin, additional, and Oldroyd, Keith G., additional more...

Published
2023
Full Text
View/download PDF

6. TCT-255 Clinical and Coronary Physiology Characteristics of Patients With Residual Angina After Percutaneous Coronary Intervention

Author

Collison, Damien, primary, Copt, Samuel, additional, Mizukami, Takuya, additional, Didagelos, Matthaios, additional, Aetesam-ur-Rahman, Muhammad, additional, McCartney, Peter, additional, Collet, Carlos, additional, Ford, Tom, additional, Lindsay, Mitchell, additional, Rocchiccioli, Paul, additional, Brogan, Richard, additional, Watkins, Stuart, additional, McEntegart, Margaret, additional, Good, Richard, additional, Robertson, Keith, additional, O’Boyle, Patrick, additional, Davie, Andrew, additional, Khan, Adnan, additional, Hood, Stuart, additional, Eteiba, Hany, additional, Berry, Colin, additional, and Oldroyd, Keith, additional more...

Published
2022
Full Text
View/download PDF

7. Coronary Flow Variations Following Percutaneous Coronary Intervention Affect Diastolic Nonhyperemic Pressure Ratios More Than the Whole Cycle Ratios

Author

Aetesam‐ur‐Rahman, Muhammad, primary, Zhao, Tian X., additional, Paques, Kitty, additional, Oliveira, Joana, additional, Khialani, Bharat, additional, Kyranis, Stephen, additional, Braganza, Denise M., additional, Clarke, Sarah C., additional, Bennett, Martin R., additional, West, Nick E. J., additional, and Hoole, Stephen P., additional more...

Published
2022
Full Text
View/download PDF

8. TICAGRELOR DOES NOT MEDIATE ITS EARLY BENEFICIAL EFFECTS IN ST-ELEVATION MYOCARDIAL INFARCTION BY IMPROVING CORONARY MICROVASCULAR DYSFUNCTION – THE TIMES DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL

Author

Hoole, Stephen P., primary, Aetesam-ur-Rahman, Muhammad, additional, Chiu, Yi-Da, additional, Zhao, Tian, additional, Paques, Kitty, additional, Oliveira, Joana, additional, Steele, Jo, additional, Duckworth, Melissa, additional, Fielding, Sarah, additional, and West, Nick E., additional more...

Published
2022
Full Text
View/download PDF

9. CORONARY STENT BALLOON INFLATION TECHNIQUE DURING PERCUTANEOUS CORONARY INTERVENTION IS IMPORTANT IN LIMITING MICROVASCULAR DYSFUNCTION: THE EMPIRE RANDOMISED CONTROLLED TRIAL

Author

Hoole, Stephen P., primary, Aetesam-ur-Rahman, Muhammad, additional, Chiu, Yi-Da, additional, Zhao, Tian, additional, Oliveira, Joana, additional, East, Clare, additional, Paques, Kitty, additional, Steele, Jo, additional, Duckworth, Melissa, additional, Fielding, Sarah, additional, and West, Nick E., additional more...

Published
2022
Full Text
View/download PDF

10. Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)

Author

Collison, Damien, primary, Didagelos, Matthaios, additional, Aetesam-ur-Rahman, Muhammad, additional, Copt, Samuel, additional, McDade, Robert, additional, McCartney, Peter, additional, Ford, Thomas J, additional, McClure, John, additional, Lindsay, Mitchell, additional, Shaukat, Aadil, additional, Rocchiccioli, Paul, additional, Brogan, Richard, additional, Watkins, Stuart, additional, McEntegart, Margaret, additional, Good, Richard, additional, Robertson, Keith, additional, O’Boyle, Patrick, additional, Davie, Andrew, additional, Khan, Adnan, additional, Hood, Stuart, additional, Eteiba, Hany, additional, Berry, Colin, additional, and Oldroyd, Keith G, additional more...

Published
2021
Full Text
View/download PDF

11. Adenosine‐Induced Coronary Steal Is Observed in Patients Presenting With ST‐Segment–Elevation Myocardial Infarction

Author

Aetesam‐ur‐Rahman, Muhammad, primary, Brown, Adam J., additional, Jaworski, Catherine, additional, Giblett, Joel P., additional, Zhao, Tian X., additional, Braganza, Denise M., additional, Clarke, Sarah C., additional, Agrawal, Bobby S. K., additional, Bennett, Martin R., additional, West, Nick E. J., additional, and Hoole, Stephen P., additional more...

Published
2021
Full Text
View/download PDF

12. Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study

Author

Zhao, Tian X, primary, Aetesam-Ur-Rahman, Muhammad, additional, Sage, Andrew P, additional, Victor, Saji, additional, Kurian, Rincy, additional, Fielding, Sarah, additional, Ait-Oufella, Hafid, additional, Chiu, Yi-Da, additional, Binder, Christoph J, additional, Mckie, Mikel, additional, Hoole, Stephen P, additional, and Mallat, Ziad, additional more...

Published
2021
Full Text
View/download PDF

13. GLP-1 Vasodilatation in Humans With Coronary Artery Disease is Not Adenosine Mediated.

Author

Aetesam-ur-Rahman, Muhammad, primary, Giblett, Joel P., additional, Khialani, Bharat, additional, Kyranis, Stephen, additional, Clarke, Sophie J., additional, Zhao, Tian X., additional, Braganza, Denise M., additional, Clarke, Sarah C., additional, West, Nick E. J., additional, Bennett, Martin R., additional, and Hoole, Stephen P., additional more...

Published
2020
Full Text
View/download PDF

14. Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study.

Author

Zhao, Tian X, Aetesam-Ur-Rahman, Muhammad, Sage, Andrew P, Victor, Saji, Kurian, Rincy, Fielding, Sarah, Ait-Oufella, Hafid, Chiu, Yi-Da, Binder, Christoph J, Mckie, Mikel, Hoole, Stephen P, and Mallat, Ziad more...

Subjects
*ST elevation myocardial infarction, *EXPERIMENTAL medicine, *MYOCARDIAL infarction, *RITUXIMAB, *B cells, *MYOCARDIAL injury
Abstract

Aims In pre-clinical models of acute myocardial infarction (MI), mature B cells mobilize inflammatory monocytes into the heart, leading to increased infarct size and deterioration of cardiac function, whilst anti-CD20 antibody-mediated depletion of B cells limits myocardial injury and improves cardiac function. Rituximab is a monoclonal anti-CD20 antibody targeted against human B cells. However, its use in cardiovascular disease is untested and is currently contraindicated. Therefore, we assessed the safety, feasibility, and pharmacodynamic effect of rituximab given to patients with acute ST-elevation MI (STEMI). Methods and results Rituximab in patients with acute ST-elevation myocardial infarction (RITA-MI) was a prospective, open-label, dose-escalation, single-arm, phase 1/2a clinical trial, which tested rituximab administered as a single intravenous dose in patients with STEMI within 48 h of symptom onset. Four escalating doses (200, 500, 700, and 1000 mg) were used. The primary endpoint was safety, whilst secondary endpoints were changes in circulating immune cell subsets including B cells, and cardiac and inflammatory biomarkers. A total of 24 patients were dosed. Rituximab appeared well tolerated. Seven serious adverse events were reported, none of which were assessed as being related to the rituximab infusion. Rituximab caused a mean 96.3% (95% confidence interval 93.8–98.8%) depletion of circulating B cells within 30 min of starting the infusion. Maximal B-cell depletion was seen at Day 6, which was significantly lower than baseline for all doses (P  < 0.001). B-cell repopulation at 6 months was dose-dependent, with modulation of returning B-cell subsets. Immunoglobulin (IgG, IgM, and IgA) levels were not affected during the 6 months of follow-up. Conclusions A single infusion of rituximab appears safe when given in the acute STEMI setting and substantially alters circulating B-cell subsets. We provide important new insight into the feasibility and pharmacodynamics of rituximab in acute STEMI, which will inform further clinical translation of this potential therapy. Clinical trial registration NCT03072199 at https://www.clinicaltrials.gov/ [ABSTRACT FROM AUTHOR] more...

Published
2022
Full Text
View/download PDF

17. GLP‐1 Is a Coronary Artery Vasodilator in Humans

Author

Clarke, Sophie J., primary, Giblett, Joel P., additional, Yang, Lucy L., additional, Hubsch, Annette, additional, Zhao, Tian, additional, Aetesam‐ur‐Rahman, Muhammad, additional, West, Nick E. J., additional, O'Sullivan, Michael, additional, Figg, Nichola, additional, Bennett, Martin, additional, Wewer Albrechtsen, Nicolai J., additional, Deacon, Carolyn F., additional, Cheriyan, Joseph, additional, and Hoole, Stephen P., additional more...

Published
2018
Full Text
View/download PDF

20. GLP-1 Is a Coronary Artery Vasodilator in Humans

Author

Clarke, Sophie J., Giblett, Joel P., Yang, Lucy L., Hubsch, Annette, Zhao, Tian, Aetesam-ur-Rahman, Muhammad, West, Nick E. J., O'Sullivan, Michael, Figg, Nichola, Bennett, Martin, Albrechtsen, Nicolai J. Wewer, Deacon, Carolyn F., Cheriyan, Joseph, Hoole, Stephen P., Clarke, Sophie J., Giblett, Joel P., Yang, Lucy L., Hubsch, Annette, Zhao, Tian, Aetesam-ur-Rahman, Muhammad, West, Nick E. J., O'Sullivan, Michael, Figg, Nichola, Bennett, Martin, Albrechtsen, Nicolai J. Wewer, Deacon, Carolyn F., Cheriyan, Joseph, and Hoole, Stephen P. more...

Abstract

Background-The mechanism underlying the beneficial cardiovascular effects of the incretin GLP-1 (glucagon-like peptide 1) and its analogues in humans is elusive. We hypothesized that activating receptors located on vascular smooth muscle cells to induce either peripheral or coronary vasodilatation mediates the cardiovascular effect of GLP-1. Methods and Results-Ten stable patients with angina awaiting left anterior descending artery stenting underwent forearm blood flow measurement using forearm plethysmography and post-percutaneous coronary intervention coronary blood flow measurement using a pressure-flow wire before and after peripheral GLP-1 administration. Coronary sinus and artery bloods were sampled for GLP-1 levels. A further 11 control patients received saline rather than GLP-1 in the coronary blood flow protocol. GLP-1 receptor (GLP-1R) expression was assessed by immunohistochemistry using a specific GLP-1R monoclonal antibody in human tissue to inform the physiological studies. There was no effect of GLP-1 on absolute forearm blood flow or forearm blood flow ratio after GLP-1, systemic hemodynamics were not affected, and no binding of GLP-1R monoclonal antibody was detected in vascular tissue. GLP-1 reduced resting coronary transit time (mean [SD], 0.87 [0.39] versus 0.63 [0.27] seconds; P=0.02) and basal microcirculatory resistance (mean [SD], 76.3 [37.9] versus 55.4 [30.4] mm Hg/s; P=0.02), whereas in controls, there was an increase in transit time (mean [SD], 0.48 [0.24] versus 0.83 [0.41] seconds; P<0.001) and basal microcirculatory resistance (mean [SD], 45.9 [34.7] versus 66.7 [37.2] mm Hg/s; P=0.02). GLP-1R monoclonal antibody binding was confirmed in ventricular tissue but not in vascular tissue, and transmyocardial GLP-1 extraction was observed. Conclusions-GLP-1 causes coronary microvascular dilation and increased flow but does not influence peripheral tone. GLP-1R immunohistochemistry suggests that GLP-1 coronary vasodilatation is indirectly more...

Published
2018

23. Complex percutaneous coronary intervention in patients unable to undergo coronary artery bypass grafting during the COVID-19 pandemic: insights from the UK-ReVasc Registry.

Author

Kite TA, Chase A, Owens CG, Shaukat A, Mozid AM, O'Kane P, Routledge H, Perera D, Jain AK, Palmer N, Hoole SP, Egred M, Sinha MK, Cahill TJ, Anantharam B, Byrne J, Morris PD, Kean S, Sabra A, Aetesam-Ur-Rahman M, Mailey J, Demir O, Mouyis K, Abdalwahab A, Terentes-Printzios D, Kanyal R, Curzen N, Berry C, Gershlick AH, and Ladwiniec A more...

Abstract

Objectives: Cardiac surgery for coronary artery disease was dramatically reduced during the first wave of the COVID-19 pandemic. Many patients with disease ordinarily treated with coronary artery bypass grafting (CABG) instead underwent percutaneous coronary intervention (PCI). We sought to describe 12-month outcomes following PCI in patients who would typically have undergone CABG., Methods: Between March 1 and July 31, 2020, patients who received revascularization with PCI when CABG would have been the primary choice of revascularization were enrolled in the prospective, multicenter UK-ReVasc Registry. We evaluated the following major adverse cardiovascular events at 12 months: all-cause mortality, myocardial infarction, repeat revascularization, stroke, major bleeding, and stent thrombosis., Results: A total of 215 patients were enrolled across 45 PCI centers in the United Kingdom. Twelve-month follow up data were obtained for 97% of the cases. There were 9 deaths (4.3%), 5 myocardial infarctions (2.4%), 12 repeat revascularizations (5.7%), 1 stroke (0.5%), 3 major bleeds (1.4%), and no cases of stent thrombosis. No difference in the primary endpoint was observed between patients who received complete vs incomplete revascularization (residual SYNTAX score £ 8 vs > 8) (P = .22)., Conclusions: In patients with patterns of coronary disease in whom CABG would have been the primary therapeutic choice outside of the pandemic, PCI was associated with acceptable outcomes at 12 months of follow-up. Contemporary randomized trials that compare PCI to CABG in such patient cohorts may be warranted. more...

Published
2024
Full Text
View/download PDF